Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Investor Investigation Over Possible Violations Of Securities Laws Announced

If you purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Alexion Pharmaceuticals
Affected Securities: 
NASDAQ: ALXN

June 24, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares over potential securities laws violations by Alexion Pharmaceuticals, Inc. and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) concerning whether a series of statements by Alexion Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Alexion Pharmaceuticals, Inc. reported that its annual Total Revenue rose from over $2.23 billion in 2014 to over $2.6 billion in 2015 while its respective Net Income declined from $656.91 million to $144.38 million.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) grew from $88.49 per share in June 2013 to as high as $204.30 per share in July 2015.

On June 6, 2016, Alexion Pharmaceuticals, Inc announced topline results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) declined from $155.78 per share on June 6, 2016 to $133.18 per share on June 13, 2016.